Differential immunomodulatory effects by Tripterygium wilfordii Hook f-derived refined extract PG27 and its purified component PG490 (triptolide) in human peripheral blood T cells: potential therapeutics for arthritis and possible mechanisms explaining in part Chinese herbal theory “Junn-Chenn-Zuou-SS”

Journal of Translational Medicine

Jenn-Haung Lai⁵  Ping Chao³  Ann Chen¹  Wen-Liang Chang²  Ling-Jun Ho⁴ 

[1] Department of Pathology, National Defense Medical Center, Taipei, Taiwan, R.O.C;School of Pharmacy, National Defense Medical Center, Taipei, Taiwan, R. O. C;Institute of Molecular Biology, Academia Sinica, Taipei, R. O. C;Graduate Institute of Basic Medical Science, PhD Program of Aging, China Medical University, Taichung, Taiwan, R. O. C;Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Tao-Yuan, Taiwan, R. O. C

关键词: T Cells;    PG490 (Triptolide);    PG27;    I-kappaBalpha kinase-beta;    Nuclear factor kappaB;    Tripterygium wilfordii Hook f;   

Others  :  824477
DOI  :  10.1186/1479-5876-11-294

 received in 2013-07-28, accepted in 2013-11-19,  发布年份 2013

【 摘 要 】

Background

For thousands of years, it remains unclear why Chinese prefer complex herbal remedy and seldom try to purify it. One of the reasons is that they believe Chinese herbs compared to Western drugs are relatively less toxic and better tolerated. The so called “Junn-Chenn-Zuou-SS” theory illustrates a concept of coordinated effects from a combination of different Chinese herbs. PG27, a refined extract from a well-known Chinese antirheumatic herb Tripterygium wilfordii Hook f (TwHf), is effective in attenuating transplantation rejection and extending survival of cardiac xenografts.

Methods

Experiments were conducted in human primary T lymphocytes isolated from buffy coat. The activities of the inhibitor of kappaB alpha kinase-inhibitor of kappaB alpha-nuclear factor kappaB (IKK-IκBα-NF-κB) and mitogen activated protein kinase-activator protein-1 (MAPK-AP-1) signaling pathways were determined via electrophoretic mobility shift assays, immunoprecipitation kinase assays, Western blots, and transfection assays.

Results

We showed that PG27 inhibited IKKα-IκBα-NF-κB and MAPK-AP-1 signaling pathways; however, IKKβ activity was less susceptible to inhibition by PG27. In contrast, the purified component of TwHf, PG490 (triptolide), reduced both MAPK-AP-1 and IKK-IκBα-NF-κB signaling pathways, including both IKKα and IKKβ, with similar potency. By means of high performance liquid chromatography analysis, it was estimated that PG490 constituted 1.27 ± 0.06% of the total PG27 content. Further analysis demonstrated that compared to PG490 alone, PG27 that contained an equal amount of PG490 was less toxic and less immunosuppressive, suggesting the presence of cytoprotective ingredient(s) in the non-PG490 components of PG27.

Conclusions

In addition to demonstrating the immunomodulatory capacity of PG27 as the potential therapeutics for arthritis and prevention of transplantation rejection, the differential regulatory effects and mechanisms by PG27 and PG490 further support in part a possibly-existing Chinese herbal theory “Junn-Chenn-Zuou-SS”.

【 授权许可】

   
2013 Ho et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]O’Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, et al.: Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013, 369:307-318.
• [2]Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF: Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem 2004, 4:895-919.
• [3]Ho LJ, Lai JH: Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. Curr Drug Metab 2004, 5:181-192.
• [4]Cameron M, Gagnier JJ, Chrubasik S: Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2011, CD002948.
• [5]Tao X, Younger J, Fan FZ, Wang B, Lipsky PE: Benefit of an extract of tripterygium wilfordii hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002, 46:1735-1743.
• [6]Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, Kivitz A, Sherrer Y, Pucino F, Csako G, et al.: Comparison of tripterygium wilfordii hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med 2009, 151:229-240. W249-251
• [7]Ho LJ, Chang DM, Chang ML, Kuo SY, Lai JH: Mechanism of immunosuppression of the antirheumatic herb TWHf in human T cells. J Rheumatol 1999, 26:14-24.
• [8]Lai JH, Ho LJ, Lu KC, Chang DM, Shaio MF, Han SH: Western and Chinese antirheumatic drug-induced T cell apoptotic DNA damage uses different caspase cascades and is independent of Fas/Fas ligand interaction. J Immunol 2001, 166:6914-6924.
• [9]Kupchan SM, Court WA, Dailey RG Jr, Gilmore CJ, Bryan RF: Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 1972, 94:7194-7195.
• [10]Tao X, Cai JJ, Lipsky PE: The identity of immunosuppressive components of the ethyl acetate extract and chloroform methanol extract (T2) of Tripterygium wilfordii Hook F. J Pharmacol Exp Ther\ 1995, 272:1305-1312.
• [11]Zhou ZL, Yang YX, Ding J, Li YC, Miao ZH: Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep 2012, 29:457-475.
• [12]Chen Y, Zeng D, Schlegel PG, Fidler J, Chao NJ: PG27, an extract of Tripterygium wilfordii hook f, induces antigen-specific tolerance in bone marrow transplantation in mice. Blood 2000, 95:705-710.
• [13]Wang J, Xu R, Jin R, Chen Z, Fidler JM: Immunosuppressive activity of the Chinese medicinal plant Tripterygium wilfordii. II. Prolongation of hamster-to-rat cardiac xenograft survival by combination therapy with the PG27 extract and cyclosporine. Transplantation 2000, 70:456-464.
• [14]Han R, Rostami-Yazdi M, Gerdes S, Mrowietz U: Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. Br J Clin Pharmacol 2012, 74:424-436.
• [15]Zhang Y, Ma X: Triptolide inhibits IL-12/IL-23 expression in APCs via CCAAT/enhancer-binding protein alpha. J Immunol 2010, 184:3866-3877.
• [16]Ruland J: Return to homeostasis: downregulation of NF-kappaB responses. Nat Immunol 2011, 12:709-714.
• [17]Hinz M, Arslan SC, Scheidereit C: It takes two to tango: IkappaBs, the multifunctional partners of NF-kappaB. Immunol Rev 2012, 246:59-76.
• [18]Kanarek N, Ben-Neriah Y: Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunol Rev 2012, 246:77-94.
• [19]Criswell LA: Gene discovery in rheumatoid arthritis highlights the CD40/NF-kappaB signaling pathway in disease pathogenesis. Immunol Rev 2010, 233:55-61.
• [20]Schonthaler HB, Guinea-Viniegra J, Wagner EF: Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis 2011, 70(Suppl 1):i109-i112.
• [21]Yang SP, Ho LJ, Lin YL, Cheng SM, Tsao TP, Chang DM, Hsu YL, Shih CY, Juan TY, Lai JH: Carvedilol, a new antioxidative beta-blocker, blocks in vitro human peripheral blood T cell activation by downregulating NF-kappaB activity. Cardiovasc Res 2003, 59:776-787.
• [22]Choi YJ, Kim TG, Kim YH, Lee SH, Kwon YK, Suh SI, Park JW, Kwon TK: Immunosuppressant PG490 (triptolide) induces apoptosis through the activation of caspase-3 and down-regulation of XIAP in U937 cells. Biochem Pharmacol 2003, 66:273-280.
• [23]Liu J, Jiang Z, Xiao J, Zhang Y, Lin S, Duan W, Yao J, Liu C, Huang X, Wang T, et al.: Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine 2009, 16:1006-1013.
• [24]Karin M, Yamamoto Y, Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004, 3:17-26.
• [25]Ruan Q, Chen YH: Nuclear factor-kappaB in immunity and inflammation: the Treg and Th17 connection. Adv Exp Med Biol 2012, 946:207-221.
• [26]Majumdar S, Aggarwal BB: Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol 2001, 167:2911-2920.
• [27]Manna SK, Mukhopadhyay A, Aggarwal BB: Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol 2000, 165:5962-5969.
• [28]Ishiyama T, Dharmarajan S, Hayama M, Moriya H, Grapperhaus K, Patterson GA: Inhibition of nuclear factor kappaB by IkappaB superrepressor gene transfer ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Thorac Cardiovasc Surg 2005, 130:194-201.
• [29]Ohmori K, Takeda S, Miyoshi S, Minami M, Nakane S, Ohta M, Sawa Y, Matsuda H: Attenuation of lung injury in allograft rejection using NF-kappaB decoy transfection-novel strategy for use in lung transplantation. Eur J Cardiothorac Surg 2005, 27:23-27.
• [30]Manning AM, Davis RJ: Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003, 2:554-565.
• [31]Sakurai H: Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 2012, 33:522-530.
• [32]Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM: Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 1985, 313:318-320.
• [33]Thalayasingam N, Isaacs JD: Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011, 25:549-567.
• [34]Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dorner T, Emery P, Fleischmann R, Gibofsky A, et al.: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012, 71(Suppl 2):i2-i45.
• [35]Suzuki J, Ogawa M, Muto S, Itai A, Isobe M, Hirata Y, Nagai R: Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases. Expert Opin Investig Drugs 2011, 20:395-405.
• [36]Li ZW, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, Johnson R, Karin M: The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 1999, 189:1839-1845.
• [37]Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV: Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 1999, 10:421-429.
• [38]Li Q, Lu Q, Hwang JY, Buscher D, Lee KF, Izpisua-Belmonte JC, Verma IM: IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 1999, 13:1322-1328.
• [39]Li ZW, Omori SA, Labuda T, Karin M, Rickert RC: IKK beta is required for peripheral B cell survival and proliferation. J Immunol 2003, 170:4630-4637.
• [40]Egan LJ, Eckmann L, Greten FR, Chae S, Li ZW, Myhre GM, Robine S, Karin M, Kagnoff MF: IkappaB-kinasebeta-dependent NF-kappaB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 2004, 101:2452-2457.